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A B S T R A C T
Zinc transporters facilitate metal mobilization and compartmentalization, playing a key role in cellular devel-
opment. Little is known about the mechanisms and pathways of Zn movement between Zn transporters and
metalloproteins during myoblast diﬀerentiation. We analyzed the diﬀerential expression of ZIP and ZnT trans-
porters during C2C12 myoblast diﬀerentiation. Zn transporters account for a transient decrease of intracellular
Zn upon myogenesis induction followed by a gradual increase of Zn in myotubes. Considering the subcellular
localization and function of each of the Zn transporters, our ﬁndings indicate that a ﬁne regulation is necessary
to maintain correct metal concentrations in the cytosol and subcellular compartments to avoid toxicity, maintain
homeostasis, and for loading metalloproteins needed during myogenesis. This study advances our basic un-
derstanding of the complex Zn transport network during muscle diﬀerentiation.
1. Introduction
Zinc (Zn) is an essential trace nutrient necessary for normal phy-
siological functions in all forms of life [1,2]. Zn is a cofactor in up to
10% of mammalian proteins and it is crucial for proper folding and for
the catalytic activity of numerous enzymes [1,3]. With a Zn-deﬁcient
diet, mammals develop anemia, growth retardation, hypogonadism,
skin abnormalities, diarrhea, neurological and mental deﬁciencies,
alopecia, taste disorders, chronic inﬂammation and compromised im-
mune function [1–6]. Conversely, excess Zn is cytotoxic and causes
deﬁcient copper absorption [7–9]. Therefore, cellular Zn homeostasis
must be tightly controlled. Two families of Zn transporters, ZnTs (so-
lute-linked carrier 30, SLC30) and ZIPs (Zrt- and Irt-like proteins,
SLC39) export and import Zn, respectively, between the cytosol, orga-
nelles, and extracellular milieu [1,2,10]. In mammals, ten ZnT (1–10)
exporters and fourteen ZIP importers (1-14) have been identiﬁed.
Nonetheless, the breadth of cellular functions for all these Zn trans-
porters remains to be elucidated. ZnTs and ZIPs are transmembrane
proteins predicted to have 6 or 8 transmembrane domains, respectively
[1,2]. ZnT5 is the exception, with nine putative transmembrane
domains [2]. Zn transport occurs in response to an ionic gradient. Most
ZnTs dimerize and export Zn by a diﬀusion-mediated Zn2+/H+ ex-
change, while ZIPs import the ion through a channel-like activity [2].
However, some ZIPs import Zn through a bicarbonate/Zn2+ symport
mechanism [11]. Certain transporters like ZIP8 and ZIP14 also trans-
port Fe, Mn, and Cd [12] while ZnT10 is the only ZnT known to pri-
marily transport Mn over Zn [13,14].
Members of the ZnT and ZIP families have a prominent role in a
wide range of developmental processes. For instance, in chondrocytes,
increased levels of cellular Zn have been associated with the presence of
ZIP8 in lysosomal vesicles, which may activate MTF1, a metal re-
sponsive transcription factor [15]. MTF1 in turn promotes the expres-
sion of metalloproteases (MMPs) that degrade diﬀerent components of
the extracellular matrix [16–19]. ZIP12 has been found to induce neu-
ronal diﬀerentiation via activation of cAMP response element binding
protein (CREB) [20]. ZIP14 transports Fe, Mn and Cd in addition to Zn
[21–23]. Interestingly, severely aﬀected phenotypes are observed in
Zip14 knock-out animals. For instance, these mice have impaired sys-
temic growth, decreased body sizes, and impaired skeletal development
due to impaired CREB activation [24]. Moreover, mice lacking Zip14
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present a proliferation defect in hepatocytes, are hypoglycemic, hy-
perinsulinemic, and have higher levels of glucose in the liver [21,25].
Importantly, CREB activation is also necessary for proper development
and function of the skeletal muscle lineage. It is required for diﬀer-
entiation of embryonic skeletal muscle progenitors, for survival of adult
skeletal muscle, for promoting myoblast proliferation in mice that were
subject to muscle injury, and also for enhancing muscle regeneration in
a dystrophic mouse model [26]. ZIP2 is induced by Zn deprivation in
monocytes, and is necessary for keratinocyte diﬀerentiation [1,27,28].
Experimental evidence suggests a major role in development for ZIP2,
as knock-out mice are sensitive to dietary Zn deﬁciency during preg-
nancy [29]. ZIP5 is required for systemic Zn excretion and to promote
the development of the sclera and retina [30–32]. Zip6 over-expression
has been associated with the epithelial-mesenchymal transition of dif-
ferent cancer types [33–37]. ZIP6 also contributes to dendritic cell
maturation [38]. ZIP1 is proposed to be involved in activation of mi-
croglia, embryonic development, and prostate metabolism [2,39–42].
ZIP4 is required for early development, dietary Zn uptake in the in-
testine, and Zn levels regulate its expression [43,44]. ZIP10-dependent
Zn signaling is required for early development of B-cells by suppressing
caspase activity in the bone marrow [45]. The above mentioned ZIPs
are located to the plasma membrane. Other ZIPs participate in Zn
transport for protein maturation, a process that occurs in intracellular
compartments. ZIP7, as an example, is located in the endoplasmic re-
ticulum (ER) and the trans Golgi network (TGN), and it has an im-
portant role in glycemic control of skeletal muscle [46]. ZIP9 is located
at the cell surface and TGN [47,48] and is considered to be an androgen
receptor in addition to its role in Zn transport [48]. ZIP13 mobilizes Zn
to the TGN and secretory vesicles, controls Zn homeostasis in the ER
and is involved in BMP/TGF-β/Smad signaling pathway [49–51].
ZnT1 is the only recognized Zn exporter located to the plasma
membrane and is essential during embryonic development, as deletion
of the ZnT1 gene in mice is embryonic lethal [52,53]. On the other
hand, the majority of the ZnT transporters are localized to secretory
structures and the TGN [2]. Their involvement in growth and diﬀer-
entiation has been reported in several cellular systems. For instance,
ZnT7 deletion causes growth retardation, decreased systemic Zn, re-
duced fat accumulation, and impaired glucose tolerance and insulin
resistance in male mice [54–56]. ZnT10 is also located in endosomal
vesicles, potentially contributing to Zn and Mn export [3]. ZnT5 acts in
the early secretory pathway, and knock-out mice for this transporter
present with growth delays, muscle weakness and cardiac deﬁciencies
[57]. A ZnT5/6 dimer mobilizes Zn to activate enzymes such as alkaline
phosphatases in the early secretory pathway [58]. Other transporters
located to the early secretory pathway and TGN are ZnT2, ZnT3 and
ZnT8. ZnT2 expression is induced by elevated Zn levels, and has been
detected in mammary glands, prostate, pancreas, small intestine,
kidney, and retina [31,59,60]. ZnT2 is necessary for secretion of Zn into
breast milk in humans [61–64]. ZnT3 is located mainly in synaptic
vesicles of glutamatergic neurons located in the hippocampus, but is
proposed to also modulate insulin production in pancreatic β cells
[65–67]. ZnT8 activity has important implications in diabetes mellitus
[68]. ZnT8 knock-out mice fed a high-fat diet became glucose intolerant
or diabetic, and islet cells became less responsive to glucose. This is due
to a failure to transport Zn into insulin granules, which has been shown
to co-crystallize with insulin in pancreatic beta cells [68,69].
Transport of Zn to the nucleus is fundamental for cell growth and
development. A large number of transcription factors require Zn for
DNA binding and activation of gene expression [70–74]. Zn binding
transcription factors can be metallated in the cytosol or subcellular
compartments, although Zn acquisition may also occur in the nucleus
[75]. Zn has also been found in the nucleolus and chromosomes, and is
implicated in DNA replication and stabilization of DNA, RNA, and ri-
bosomes [76]. ZIP11 is the only transporter proposed to be located at
the nucleus, although no information on its cellular role is available
[77]. Finally, ZnT9 homology to the ZnT family is under debate, as it
lacks the distinguishing ZnT transmembrane Zn-binding domains and is
mainly located in the cytoplasm [78,79]. ZnT9 acts as nuclear receptor
coactivator and was renamed as GAC63 [78].
In spite of all this accumulated research, little is known about Zn
requirements, regulation, and distribution in diﬀerentiating skeletal
muscle cells. Because the majority of Zn in mammalian cells is bound to
metalloenzymes and stored in organelles and cellular vesicles, free zinc
levels remain quite low [2,80–84]. Within the cell, about 50% of Zn is
found in the cytoplasm and in vesicles, 30–40% in the nucleus, and
about 10% in the cell membrane [85,86]. Moreover, 60% of the total
systemic Zn is sequestered and used in skeletal muscle, making this
organ the greatest reservoir of Zn in the body [87]. Whether Zn is ne-
cessary for myoblast diﬀerentiation is a matter of controversy. Experi-
mental evidence suggests that addition of Zn to diﬀerentiation medium
inhibits myogenesis, but promotes myoblast proliferation and activa-
tion of quiescent myogenic satellite cells [88]. Yet other evidence de-
monstrated that Zn is required for diﬀerentiation, as myoblast diﬀer-
entiation in both C2C12 cells and chicken embryo myoblasts was
inhibited in Zn-deﬁcient medium [88,89]. Furthermore, mice fed with a
Zn-deﬁcient diet may have reduced muscle regeneration upon injury
[4]. C2C12 myoblasts are an excellent model to study myogenesis due
to their similarities to progenitor myogenic lines [90]. Upon serum
depletion, the cells commit to diﬀerentiate and the myoblasts fuse to-
gether to become multinucleated myotubes. Myoblasts express speciﬁc
regulators of the skeletal muscle lineage like MyoD, myogenic factor 5
(Myf5), and myogenin. Upon induction of diﬀerentiation, MyoD and
Myf5 drive the expression of myogenin, a transcription factor funda-
mental for the coordination of skeletal muscle development and repair.
Once the myoblasts commit to diﬀerentiate, myogenin expression
continues to increase as myogenesis progresses leading to the expres-
sion of muscle-speciﬁc proteins such as myosin heavy chains, skeletal
actin, muscle-speciﬁc creatine kinase and MMPs, among others. Ad-
ditionally, myoﬁbers express insulin receptors and require insulin
binding for growth [90].
We hypothesized that the intracellular levels of Zn in diﬀerentiating
myoblasts is tightly controlled by a timely and diﬀerential expression of
ZnT and ZIP transporters that is speciﬁc to the skeletal muscle lineage.
The C2C12 stable murine cell line was used as a model of myogenesis.
We analyzed the kinetics of Zn accumulation at diﬀerent stages of this
process. Dynamic changes of Zn levels were observed over the course of
myogenic diﬀerentiation. Gene and protein expression analyses suggest
that cellular changes in Zn content in myogenesis may be dependent
mainly on four ZIP transporters located at the plasma membrane (ZIP3,
8, 5 and 6), and four transporters located in subcellular compartments
(ZnT7, 4, 8 and ZIP11). This study set the basis for understanding how
Zn is distributed and potentially ultilized during skeletal muscle dif-
ferentiation.
2. Materials and methods
2.1. Cell culture
C2C12 cells are immortalized mouse myoblast used as a in vitro
model for myogenesis studies. C2C12 cells proliferate rapidly under
high serum conditions, and undergo myogenic diﬀerentiation under
low serum conditions [91,92]. C2C12 myoblasts were seeded at
1× 104 cells/cm2 in DMEM media containing 10% fetal bovine serum
(Gibco) to support proliferation. After 48 h, cells reached conﬂuence,
and the media was changed to diﬀerentiation media (DMEM, 2% horse
serum). At least three independent biological replicates were collected
for analysis at diﬀerent time points of proliferation for 24 h (P) and
throughout myogeneic diﬀerentiation (0, 3, 6, 12, 24, 48, and 72 h).
2.2. Whole cell Zn content analysis
C2C12 cells from the indicated time points were rinsed three times
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and immediatly re-suspended in 100 μl of PBS. Cells were lysed by three
sonication cycles (30 s on by 30 s oﬀ) for 5min at medium intensity
using a Bioruptor UCD-200 (Diagenode). Total protein content was
determined by Bradford [93]. Then, samples were acid digested in
concentrated HNO3 (trace metal grade) for 1 h at 80 °C and overnight at
20 °C. Digestions were concluded by adding 30 μl H2O2 [94–97]. The
resulting solution was measured by triplicate using atomic absorption
spectroscopy (AAS) equipped with a graphite furnace (PerkinElmer,
Aanalyst 800), which provides an ideal limit of detection (LOD) of Zn
from currently available techniques [98]. The estimated LOD, calcu-
lated as 3σ of 0.01 μmol L−1, allowed quantiﬁcation of all samples. The
quantiﬁcation of Zn, at the ppb level, was completed using analytical
grade standards diluted in 18 MΩ puriﬁed water. Concentration of Zn
measured via AAS was normalized to the initial mass of protein in each
sample.
2.3. Zinc imaging
Proliferating and diﬀerentiating C2C12 cells were loaded with 2 μM
Fluo-Zin3 AM, cell permeant (Invitrogen) in the corresponding culture
media for 40min at 37 °C. Fluo-Zin3 has a high aﬃnity to bind Zn2+.
Then, the cells were washed with fresh media and allowed to rest for
another 20min at 37 °C. For live imaging of Zn the media was ex-
changed for PBS right before microscopic analyses, to avoid ﬂuorescent
interference of the culture media. In addition, cells were ﬁxed with 10%
formalin-PBS and counterstained with DAPI. Fluorescence images were
obtained with a Leica TCS SP5 II AOBS confocal laser-scanning mi-
croscope (Leica).
2.4. Gene expression analysis of Zn transporters
RNA was puriﬁed from at least three independent biological re-
plicates of proliferating and diﬀerentiated primary myoblasts with
TRIzol (Invitrogen). cDNA was synthesized using SuperScript III First-
Strand Synthesis SuperMix (ThermoFisher Scientiﬁc). Quantitative RT-
PCR was performed with Fast SYBR green master mix (ThermoFisher
Scientiﬁc) on the ABI StepOne Plus Sequence Detection System
(Applied Biosystems) using the primers listed in Supp. Table 1 and
normalized to the levels of the housekeeping gene Ef1-α.
2.5. Western blot analysis
C2C12 cells were washed with PBS and solubilized with RIPA buﬀer
(10mM piperazine-N,N-bis(2-ethanesulfonic acid), pH 7.4, 150mM
NaCl, 2 mM ethylenediamine-tetraacetic acid (EDTA), 1% Triton X-100,
0.5% sodium deoxycholate, and 10% glycerol) containing complete
protease inhibitor cocktail. Protein content was quantiﬁed by Bradford
[93]. Samples (20 μg) were resolved by SDS-PAGE and electro-
transferred to PVDF membranes (Millipore). The proteins of interest
were detected with the speciﬁc antibodies (Supp. Table 2), followed by
species-appropriate HRP-conjugated secondary antibodies and chemi-
luminescent detection (ECL PLUS; GE Healthcare). GAPDH was used as
a loading control.
2.6. Immunocytochemistry
Proliferating and diﬀerentiating C2C12 cells were ﬁxed overnight in
10% formalin-PBS at 4 °C. Samples were washed with PBS and in-
cubated overnight with Hybridoma supernatants against myogenic
markers (Supp. Table 2) in PBS buﬀer containing 5% horse serum and
0.2% Triton X-100. Secondary antibody binding and HRP staining were
performed with the universal ABC kit (Vector Labs).
3. Results
We ﬁrst asked whether cellular concentration of Zn varies as a
function of the myogenic program. To address this question, we ana-
lyzed Zn levels in proliferating and diﬀerentiating C2C12 cells (Fig. 1).
Samples were collected and whole cell metal content was determined
by AAS. Analyses detected 0.93 ± 0.09 μmol Zn/mg of protein in
proliferating myoblasts (Fig. 1A). Confocal microscopy of live and ﬁxed
proliferating myoblasts using Fluo-Zin3 showed that free Zn2+ is lo-
cated in cytosolic vesicles (Figs. 1B; Supp. S2). Whole cell Zn content
signiﬁcantly decreased when the diﬀerentiation program was initiated
at 0 h (0.32 ± 0.02 μmol Zn/mg of protein; Fig. 1A). Fluorescent la-
belling of Zn2+ is in agreement with the quantitative analysis by AAS,
and showed a large decrease of unbound Zn-contaning vesicles
(Figs. 1B; Supp. S2). After 12 h of diﬀerentiation, a gradual increase in
cytosolic Zn was detected, reaching a maximal level in mature myo-
tubes at 72 h (2.3 ± 0.3 μmol Zn/mg of protein; Fig. 1A). Fluo-Zin3
imaging also showed a gradual and sustained increase of cytosolic Zn2+
after 12 h, and until 72 h (Figs. 1B; Supp. S2), suggesting that the cel-
lular Zn content is dynamic over the course of myogenesis. AAS analysis
of Zn levels in both, proliferation and diﬀerentiation culture media
showed no signiﬁcant diﬀerences as indicated in Supp. Table 3, which
support the idea that the Zn variations in the cells are independent of
Fig. 1. Changes in Zn content in proliferating and diﬀer-
entiating C2C12 murine myoblasts. (A) Whole cell Zn content
was determined by furnace AAS and normalized to protein
content in the sample. Data represent the average of three
independent experiments +/− S.E; Student T-test comparing
the diﬀerentiation time points to proliferating cells;
*P < 0.005. (B) Representative confocal images of three in-
dependent biological experiments of live proliferating and
diﬀerentiating myoblasts labeled with Fluo-Zin3 (green) and
the corresponding bright ﬁeld image (BF) (For interpretation
of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article).
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the metal levels in the media.
We then asked which transporters, among all the recognized ZIPs
and ZnTs, might be responsible for those changes. Therefore, we in-
vestigated whether myogenesis prompts transcriptional changes in Zn
transporters located in the cell membrane of diﬀerentiating C2C12
myoblasts. Most of the transporters in the cell membrane belong to the
ZIP family [1,2,11]. We found that Zip3 and Zip8 were upregulated over
the course of myogenesis (Fig. 2). Zip3 showed the greatest increase in
expression, starting at 12 h and going up to 20 fold-change by 72 h
(Fig. 2A). ZIP3 is proposed to participate in Zn reuptake in other cel-
lular systems [99], which is consistent with its expression at early
stages of myogenesis (Fig. 2E). Zip8 mRNA exhibited a 4-fold increase
12–48 h after initiation of diﬀerentiation (Fig. 2B), but protein accu-
mulation peaked in mature myotubes (Fig. 2E). Considering the gradual
increase in Zn levels after 12 h of diﬀerentiation (Fig. 1), ZIP3 and 8
might participate in Zn re-uptake after the initial stages of myogenesis.
ZIP8 could also contribute to the establishment of the diﬀerentiated
phenotype by promoting the expression of MTF1 and trans-activation of
MMPs, which are necessary for myotube fusion [15]. Zip5 and Zip6
transcripts were upregulated during the early stages of C2C12 diﬀer-
entiation, showing a peak at 12 h after induction of myogenesis
(Fig. 2C,D); in both cases, the protein levels were constant during the
ﬁrst 12 h of diﬀerentation, and decreased after 24 h. Additional genes
encoding for Zn importers located at the cell membrane (Zip1, 2, 4, 10,
12, 14) had moderate changes in expression during myogenesis (Supp.
Fig. 3A–F), and basal protein levels were sustained over time (Supp. Fig.
S3H). Some of these transporters have been implicated in the devel-
opment and diﬀerentiation of several tissues [2]. Nonetheless, it seems
from our data that their role in skeletal muscle diﬀerentiation might be
secondary. Altogether, our data indicate that changes in Zip expression,
both transient and sustained over time, accompany changes in Zn
content during myogenesis.
ZnT1 is the only proposed Zn exporter located to the plasma
membrane [52]. Considering the signiﬁcant decrease in the cellular
levels of Zn during the initial hours of diﬀerentiation of C2C12 cells
(Figs. 1, Supp. S2), we expected a major change in the expression of
ZnT1. However, ZnT1 gene expression and protein abundance re-
mained stable during diﬀerentiation of C2C12 cells (Supp. Fig. 3G, H);
Fig. 2. Expression proﬁle of Zn importers located at the cell membrane during C2C12 diﬀerentiation. Gene expression proﬁles of Zip3 (A), Zip8 (B), Zip5 (C), Zip6 (D).
Data represent the mean of at least three independent experiments ± S.E; Student T-test comparing the diﬀerentiation time points to proliferating cells; *P < 0.01.
(E) Representative Western blots of ZIP3, ZIP8, ZIP5 and ZIP6. GAPDH as loading control.
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suggesting that the early decrease in Zn in diﬀerentiating myoblasts
may occur via additional transporters localized to distinct secretory
elements.
Metal acquisition by enzymes is a post-translational modiﬁcation
critical for folding and catalytic activity, which in some cases occurs in
the ER and TGN [100–102]. Therefore, we analyzed the expression
patterns of transporters located in these compartments. ZnT7 mRNA
expression peaked 12 h after induction of diﬀerentiation of C2C12 cells
(Fig. 3A). ZnT7 participates in signaling pathways which involve the
insulin receptor substrate 2 and AKT, which may have an important
role for myogenesis [56]. Expression of other ER and TGN transporters,
like ZIP7, remained constant during C2C12 diﬀerentiation, suggesting
its constitutive expression (Supp. Fig. S4A), which is in agreement with
a role for this transporter in glycemic control of skeletal muscles [46]. A
modest increase in Zip9 and ZnT10 transcript levels was observed
(Supp. Fig. S4B, C); however, Western blot analyses showed a diﬀer-
ential increase in abundance of these two proteins at early (ZIP9) or late
(ZnT10) stages of diﬀerentiation (Supp. Fig. S4J). Importantly, homo-
zygous mutations of ZnT10 produces muscle-related pathologies like
Parkinsonism and dystonia with hypermanganesemia [103,104]. These
muscular defects are consistent with abnormalities of mature tissue,
supporting a role for ZnT10 in fully developed skeletal muscle cells.
Then, we analyzed the expression of Zn transporters located in
compartments of the secretory route: lysosomes, endosomal vesicles,
and secretory granules. These transporters potentially contribute to the
metallation of secreted Zn-binding proteins. ZnT4 is an exporter asso-
ciated with the secretory route. Interestingly, ZnT4 mRNA expression
was induced during myogenesis (Fig. 3B). However, a decrease in the
protein abundance was observed at early time points (Fig. 3E). Con-
sidering our quantiﬁcation of Zn by AAS and confocal microscopy ob-
servations of Zn distribution (Figs. 1; Supp. S2), it is plausible that ZnT4
is responsible for Zn export via cytoplasmic vesicles, which is partially
supported by Western blot analyses showing a decrease in protein levels
early in diﬀerentiation (Fig. 3E). However, the mechanisms by which
ZnT4 may fulﬁll this role remain to be elucidated and are beyond the
scope of this paper. ZIP13, ZnT6, and ZnT5 are localized to secretory
vesicles [2,68]. Zip13 and ZnT6 showed a modest but signiﬁcant in-
crease in diﬀerentiating C2C12 cells (Supp. Fig. S4D, E). A role for
ZIP13 in myogenesis might be hypothezised, as lack of functional ZIP13
is related to Ehlers-Danlos syndrome, which is characterized by skeletal
and connective tissue abnormalities [49,51,105]. Both ZnT5 gene and
protein showed a non-signiﬁcant but observable 2-fold increase in ex-
pression after 72 h of diﬀerentiation (Supp. Fig. S4F, J). Constitutive
expression of ZnT5 in developing skeletal muscle cells is consistent with
the observation that knock-out mice for this transporter have delayed
growth, muscle weakness and cardiac deﬁciencies [57]. ZnT2 also lo-
cated in secretory vesicles, exhibited a small but signiﬁcant increase in
expression at late stages of myogenesis, when the myotubes are formed
(Supp. Fig. S4G, J). Expression of ZnT2 has been associated with ele-
vated Zn levels; considering that diﬀerentiated myotubes contain
higher levels of Zn, ZnT2 expression was expected [59].
The exporter ZnT8 is localized to secretory granules, insulin gran-
ules, and endosomal membranes [68]. Of all transporters examined
during C2C12 myoblast diﬀerentiation, ZnT8 was the only down-
regulated gene. ZnT8 reached its lowest expression level at 24 h and
was expressed once the cells were fully diﬀerentiated (Fig. 3C, E). In-
sulin is critical for muscle growth and development as more than 80%
of systemic glucose usage occurs in skeletal muscle and because failure
in insulin signaling leads to muscle atrophy [90,106]. Considering the
high demand for glucose transport for carbohydrate metabolism in
mature myotubes, we hypothesize that ZnT8-dependent Zn transport
and/or compartmentalization has a role in insulin metabolism at late
stages of myogenesis, which may explain the late expression of ZnT8. In
line with this rationale, ZnT3 is also implicated in insulin metabolism
[67]. A transient increase on ZnT3 mRNA and protein expression was
found during early stages of diﬀerentiation of C2C12 cells, (Supp. Fig.
S4H, J), suggesting that ZnT3 might partially participate in the insulin
signaling pathways during early stages of myogenesis, when ZnT8 is
downregulated.
ZIP11 is the only transporter proposed to be located in the nucleus
and TGN [2]. Zip11 mRNA and was upregulated in diﬀerentiating
C2C12 myoblasts (Fig. 3D. However, the protein expression pattern was
unusual, as ZIP11 could not be detected at 24 and 48 h and increased in
mature myoblasts, at 72 h (Fig. 3E). This eﬀect is probably due to
protein de-stabilization related to signaling induced by the diﬀer-
entiation stimulus, which is followed by protein induction at later
times, due to the increased mRNA production. The contributions of
ZIP11 to myogenesis remain to be elucidated and are beyond the scope
of this study. Finally, we analyzed the expression of ZnT9 which is
thought to be a nuclear receptor coactivator [78]. Both ZnT9 gene ex-
pression and protein levels increased after 72 h of diﬀerentiation (Supp.
Fig. S4I, J). The later recovery of ZIP11 and ZnT9 reﬂects a preferential
Fig. 3. Expression proﬁles of Zn transporters
found in subcellular compartments during
C2C12 diﬀerentiation. Gene expression proﬁles
of the transporters located in the ER and TGN:
ZnT7 (A), ZnT4 (B), ZnT8 (C) and Zip11 (D).
Data represent the mean of at least three in-
dependent experiments +/− S.E; two-tailed
unpaired t-test; *P < 0.01. Representative
Western blots of ZnT7, ZnT4, ZnT8 and ZIP11.
GAPDH as loading control.
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role for these proteins and for nuclear Zn in mature myotubes, which is
worth exploring in the future.
4. Conclusions
The expression, localization, and roles of Zn transporters in diﬀerent
tissues and stages of development are largely unknown. In this study we
investigated the diﬀerential expression of Zn transporters and how in-
tracellular levels of Zn vary during diﬀerentiation of C2C12 myoblasts.
We found that Zn levels decrease during early stages of myogenesis,
only to be restored by 12 h after the initiation of the myogenic program.
Zn levels continue to increase until the end of the diﬀerentiation period.
We also found that the majority of the transporters were transiently
expressed as a consequence of the myogenic program and were often
detected during the ﬁrst 12 h upon induction of diﬀerentiation. Only
ZnT8 was down-regulated in diﬀerentiating C2C12 cells. Our data
suggest that myogenesis requires speciﬁc and optimal Zn levels in dif-
ferent subcellular compartments. Where most of this Zn is needed re-
mains unclear, but our data indicate that a variety of Zn-binding pro-
teins secreted from cellular organelles and granules are most likely
necessary during myogenesis. Our ﬁndings also suggest that a dynamic
network of transport and distribution of Zn occurs as a consequence of
initiation of myoblast diﬀerentiation.
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